The financial terms of the deal were not disclosed.
The purchase will enable the Dutch medtech giant to expand its diagnostic and therapeutic devices portfolio with advanced venous stents. The result will be a complete procedural solution for peripheral artery disease (PAD) treatment, according to Philips.
“The acquisition of Vesper Medical is another step in our objective to innovate patient treatment with more sophisticated technology and expand our growth in the vascular therapy space,” said Chris Landon, SVP and GM of Image Guided Therapy Devices at Philips.
“Leveraging our significant procedural expertise, we see strong clinical synergies between Vesper Medical’s innovative stenting solution and our existing peripheral vascular offering,” Landon said. “This combined offering will help to better support clinicians to decide, guide, treat and confirm during the procedure, thereby enhancing patient care.”
Vesper Medical is the maker of the Vesper DUO Venous Stent System meant to treat deep venous obstruction. The company boasts that the DUO is uniquely engineered to address the multiple anatomical challenges of the deep venous system.